Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solitary Pulmonary Nodule 1Rectal Neoplasms 1Pain, Postoperative 1Lymphedema 1Lung Neoplasms 1Carcinoma, Ductal 1Anatomic Stage IV Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 44Carboplatin 35Paclitaxel 27Specimen Handling 18Cyclophosphamide 16Capecitabine 16Magnetic Resonance Spectroscopy 14sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9Doxorubicin 8olaparib 7Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Fulvestrant 4Epirubicin 4Bevacizumab 4veliparib 3famitinib 3abemaciclib 3Vinorelbine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Mastectomy, Segmental × 90 days × Clear all
NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡